Genome-wide studies in prostate cancer poised liquid biopsy as a molecular discovery tool

Frontiers in Oncology

Oncology

Nicholas Lo¹  Housheng Hansen He²  Sujun Chen³ 

[1] Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada;Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;West China School of Public Health, West China Fourth Hospital, and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China;

关键词: prostate cancer;    liquid biopsy;    deep genomic sequencing;    genome-wide methylation analysis;    disease progression;   

DOI  :  10.3389/fonc.2023.1185013

 received in 2023-03-13, accepted in 2023-08-10,  发布年份 2023

来源: Frontiers

【 摘 要 】

Liquid biopsy is emerging as an intriguing tool in clinical disease detection and monitoring. Compared to a standard tissue biopsy, performing a liquid biopsy incurs minimal invasiveness, captures comprehensive disease representation, and can be more sensitive at an early stage. Recent genome-wide liquid biopsy studies in prostate cancer analyzing plasma samples have provided insights into the genome and epigenome dynamics during disease progression. In-depth genomic sequencing can offer a comprehensive understanding of cancer evolution, enabling more accurate clinical decision-making. Furthermore, exploring beyond the DNA sequence itself provides opportunities to investigate the regulatory mechanisms underlying various disease phenotypes. Here, we summarize these advances and offer prospects for their future application.

【 授权许可】

Unknown   
Copyright © 2023 Lo, He and Chen